팔벨라 테라퓨틱스(PVLA)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $150.56 (-2.44%), 시가총액 $1.63B, 52주 최저~최고 $20.51 ~ $148.34.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
팔벨라 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
팔벨라 테라퓨틱스의 현재 주가는 $150.56 (-2.44%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
팔벨라 테라퓨틱스의 시가총액은 약 $1.63B입니다.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company